AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Will PharmaTher be the next company to get a psychedelic medicine to market? The post PharmaTher Submits New Drug Application to the FDA appeared first...
The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs. The post Cybin Granted U.S. Patent for 5-MeO-DMT appeared...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small...
MindBio Therapeutics Corp. reported it has made a major discovery from genetic testing clinical trial participants in the largest LSD-Microdosing randomized...
Cybin and Small Pharma holders will own around 74.5% and 25.5% of the combined company, respectively. The post Cybin Acquires Small Pharma in All-Share...
The companies say they will have the most substantial dataset on the DMT molecule in the industry and largest IP portfolio The post Cybin inks agreement...
In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial. The post Breaking News: Cybin to Acquire...
VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) — MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based... The post InvestmentPitch...
The psychedelic industry is changing and growing rapidly. Psychedelic medicines are being catapulted into the mainstream, and these top 10 psychedelic...